Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623391 | 0.94 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AGAANPC1 | |
| SCHEMBL11018306 | 0.83 | NPC1 (0.43) | ALDH1A1MEN1KMT2ANPC1POLB | |
| Hydrochloric Acid SCHEMBL9823989 | 0.82 | NPC1 (0.42) | ALDH1A1MEN1KMT2ANPC1POLB | |
| SCHEMBL13154657 | 0.73 | POLB (0.43) | ALDH1A1MEN1KMT2AGAANPC1 | |
| SCHEMBL7092665 | 0.73 | HPGDS (0.40) | ALDH1A1MEN1KMT2AGAAHTT | |
| SCHEMBL13154647 | 0.70 | NPC1 (0.43) | ALDH1A1MEN1KMT2AGAANPC1 | |
| SCHEMBL4793575 | 0.70 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AGAANPC1 | |
| SCHEMBL150476 | 0.70 | NPC1 (0.65) | ALDH1A1MEN1KMT2ANPC1POLB | |
| SCHEMBL29350099 | 0.70 | NPC1 (0.65) | ALDH1A1MEN1KMT2ANPC1POLB | |
| SCHEMBL5757843 | 0.68 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007118139-A9 | DRUG ELUTING STRUCTURALLY VARIABLE STENT | VASCULAR CONCEPTS HOLDINGS LTD (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007118139-A2 | DRUG ELUTING STRUCTURALLY VARIABLE STENT | VASCULAR CONCEPTS HOLDINGS LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007002133-A2 | STRUCTURALLY VARIABLE STENTS | JAYARAMAN SWAMINATHAN (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060224234-A1 | Drug eluting structurally variable stent | VASCULAR CONCEPTS HOLDINGS LIMITED (GB) | 2006-10-05 | — | — | US | disclosed |
| US-20060004437-A1 | Structurally variable stents | VASCULAR CONCEPTS HOLDINGS LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| US-20040137066-A1 | Rationally designed therapeutic intravascular implant coating | VASCULAR CONCEPTS HOLDINGS LIMITED (GB) | 2004-07-15 | — | — | US | disclosed |
| EP-1268487-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6608048-B2 | Treatment of cancer, polycystic kidney disease and colonic polyps in mammals | WYETH HOLDINGS | 2003-08-19 | — | — | US | disclosed |
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1268487-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072758-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | PKD1, PKD2, PKN1 | ALDH1A1 4115/4885MEN1 1566/4885KMT2A 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.